| Similar Articles |
|---|
 |
Pharmaceutical Executive
December 1, 2010
William Looney |
In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China.   |
Pharmaceutical Executive
October 1, 2010 |
Nobel Laureate Elie Wiesel Exclusive Interview Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge? |
Pharmaceutical Executive
December 1, 2010 |
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. |
Pharmaceutical Executive
June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
Pharmaceutical Executive
February 1, 2011
Jill Wechsler |
The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome? |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Pharmaceutical Executive
March 1, 2014
William Looney |
The Community Ethic Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. |
Pharmaceutical Executive
May 1, 2011
William Looney |
Keeping Your Place on the Nifty 50 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era. |
Pharmaceutical Executive
December 1, 2011
William Looney |
The Medicines Adherence Challenge Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma, but is it? An expert round table examines how best to make progress and agree on some practical steps for incorporation in the campaign agenda. |
Pharmaceutical Executive
November 1, 2013
William Looney |
Payers: Late for the Party? Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry. |
Pharmaceutical Executive
December 1, 2012
William Looney |
The Puzzle Master: Dr. Guido Rasi Europe's chief regulator charts a strategy from many moving parts. |
Pharmaceutical Executive
September 1, 2010 |
Looking Beyond the Patent Cliff Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP. |
Pharmaceutical Executive
December 1, 2011
William Looney |
2011: End of the Beginning The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item. |
Pharmaceutical Executive
September 1, 2010
William Looney |
The Coming Second Act Reinvention takes more than a pithy redraft of the strategy plan or mission statement; money, a change in business culture, and the mindset of thousands of employees is required too. |
Pharmaceutical Executive
January 1, 2012
William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive
May 1, 2012
William Looney |
Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever. |
Pharmaceutical Executive
April 1, 2011
William Looney |
Platforms for Peerless Performance A true performance culture has to focus on the mundane as much as the sublime. |
Pharmaceutical Executive
April 1, 2011 |
How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry. |
Pharmaceutical Executive
August 1, 2011
William Looney |
Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation. |
Pharmaceutical Executive
October 1, 2011
William Looney |
The Gathering Profiles of 30 of the pharmaceutical industry's key influences of the last three decades. |
Pharmaceutical Executive
April 1, 2014
William Looney |
The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines. |
Pharmaceutical Executive
April 1, 2011
Jeff Schindler |
Pharm Exec Wins a Neal Award! Pharm Exec's Editor-in-Chief William Looney was honored March 10 at American Business Media's Neal Awards for "Best Commentary" for his monthly editorial columns. |
Pharmaceutical Executive
August 1, 2011
William Looney |
Paying for Health -- The Right Way What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive
June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
Pharmaceutical Executive
January 1, 2012
William Looney |
The Well of Engagement We sometimes forget that the business of healthcare is also the source of a huge opportunity: improving the human condition. |
Pharmaceutical Executive
March 1, 2011 |
Pharm Exec's Seventh Annual Media Audit Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation. |
Pharmaceutical Executive
September 1, 2012
William Looney |
The Margin Call Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns. |
Pharmaceutical Executive
November 1, 2012
Clark Herman |
Prix Galien: Night at the Museum Representatives of Big Pharma and trade association leaders at the New York Museum of Natural History had one purpose in mind: to recognize the latest innovations in new drugs and medical devices. |
Pharmaceutical Executive
August 1, 2014
William Looney |
A Window on the Industry: The Emerging Pharma Leaders 2014 Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success. |
Pharmaceutical Executive
February 1, 2012
William Looney |
Brand Success: It's Not Serendipity A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure. |
Pharmaceutical Executive
July 10, 2014
William Looney |
Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead. |
Pharmaceutical Executive
October 1, 2010
William Looney |
Community: The Business of Life There is a practical lesson of reaching forward to tap the human community - and the moral connection - that will preserve the "license to operate" in the biopharmaceuticals business: the business of life. |
Pharmaceutical Executive
September 1, 2011
Richard Barker |
Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science. |
Pharmaceutical Executive
May 1, 2014
William Looney |
What's Real in Deals Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis: specialization and value differentiation are preferable to sheer bulk. |
Pharmaceutical Executive
July 1, 2012
William Looney |
Less, But Better Pharm Exec's 2012 roster of Emerging Leaders is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace. |
Pharmaceutical Executive
August 1, 2014
William Looney |
A Mission to Transform Mid-career students at Brown University's new Executive Masters in Healthcare Leadership program are challenging the status quo with workplace projects focused on one thing: removing the organizational silos. |
Pharmaceutical Executive
January 21, 2014
William Looney |
For Russia -- Tough Love Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exist. |
Pharmaceutical Executive
July 1, 2012
Ben Comer |
John Lechleiter on PhRMA and Innovation Eli Lilly CEO John Lechleiter on his agenda as incoming chairman of PhRMA, US healthcare reform, the euro crisis, and the small problem, of innovation. |
Pharmaceutical Executive
July 1, 2011
William Looney |
Truth Found in the Wrong Places More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them. |
Pharmaceutical Executive
November 1, 2011
Jeff Schindler |
Fostering a Legacy of Leadership Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York. |
Pharmaceutical Executive
August 1, 2012
William Looney |
The Phrase that Plays The FDA is creatively applying regulatory fiat to force fundamental changes in company culture. |
Pharmaceutical Executive
January 21, 2014
William Looney |
Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector |
Pharmaceutical Executive
May 1, 2012
William Looney |
Information Overload Data has become as important as the drug in driving success in healthcare. |
Pharmaceutical Executive
June 1, 2012
William Looney |
From the Editor:The Connections Game As the old Broadway song goes, June is busting out all over, and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous. |
Pharmaceutical Executive
April 1, 2012
William Looney |
IP: Time for a Reset? Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late. |
Pharmaceutical Executive
July 1, 2013
William Looney |
Talent, Terror, and the Turnaround We offer news on 15 new Emerging Pharma Leaders, business innovation, and terrorism threats to the pharmaceutical industry. |
Pharmaceutical Executive
August 1, 2013
William Looney |
One Company -- One Moment The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China -- ironically, the country touted as guarantor of our industry's future. |
Pharmaceutical Executive
January 1, 2006
Patrick Clinton |
From the Editor: A Wild 25 This has been an amazing quarter century for the pharmaceuticals industry, and it has brought us to a point at which the next quarter century can only be more of the same |
